Prostate Recruiting Phase 2 Trials for Olaparib (DB09074)

IndicationStatusPhase
DBCOND0029764 (Prostate)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03047135Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker AnalysisTreatment